Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

122861-53-4Doxycycline EP Impurity F

● Auf Lager

Katalog-Nr.::	VL159002
CAS-Nr.::	122861-53-4
Summenformel::	C23H25NO8
Molare Masse::	443.45 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 122861-53-4

Parent drug

Doxycycline

IUPAC-Name

(4S,4aR,5S,5aR,6R,12aS)-2-acetyl-4-(dimethylamino)- 3,5,10,12,12a-pentahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,11(4H,5H)-dione

Pharmakopöe-Synonyme

2-Acetyl 2-Decarbamoyl Doxycycline; Doxycycline Related Compound F

Other Synonyms

1,11(4H,5H)-Naphthacenedione, 2-acetyl-4-(dimethylamino)-4a,5a,6,12a-tetrahydro-3,5,10,12,12a-pentahydroxy-6-methyl-, (4S,4aR,5S,5aR,6R,12aS)-

Smile

O=C1C(C(C)=O)=C(O)[C@@H](N(C)C)[C@@]2([H])[C@]1(O)C(O)=C(C(C3=C(O)C=CC=C3[C@@H]4C)=O)[C@]4([H])[C@@H]2O

InChI

InChI=1S/C23H25NO8/c1-8-10-6-5-7-11(26)14(10)18(27)15-12(8)19(28)16-17(24(3)4)20(29)13(9(2)25)21(30)23(16,32)22(15)31/h5-8,12,16-17,19,26-28,30,32H,1-4H3/t8-,12+,16+,17-,19-,23+/m0/s1

Shipping Condition

Ambient Temperature

Characterization Data (Included)

HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, and Structure Elucidation Report (SER).

Additional Characterization Data

QNMR, D2O Exchange, 13C NMR, 13C APT, COSY NMR, NOESY NMR, 15N NMR, HSQC NMR, HMQC NMR, and HMBC NMR. These are available upon request and may be free or subject to additional charges.

Beschreibung

Doxycycline EP Impurity F, also known in pharmacopoeias as 2-Acetyl 2-Decarbamoyl Doxycycline; Doxycycline Related Compound F, is a highly characterized reference material. It fully complies with stringent regulatory standards, including those set by USP, EMA, JP, and BP. This product is essential for use in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of Doxycycline. Moreover, it comes with a detailed Structure Elucidation Report (SER), ensuring its accuracy and reliability for a wide range of analytical applications.

References

‚Smith, kelly, and James J. Leyden. “Safety of Doxycycline and Minocycline: A Systematic Review.” Clinical Therapeutics, vol. 27, no. 9, Sept. 2005, pp. 1329–42, https://doi.org/10.1016/j.clinthera.2005.09.005. ?Saivin, S., and G. Houin. “Clinical Pharmacokinetics of Doxycycline and Minocycline.” Clinical Pharmacokinetics, vol. 15, no. 6, Dec. 1988, pp. 355–66, https://doi.org/10.2165/00003088-198815060-00001 ‚